Prognostic value of matrix metalloproteinase 9 expression in patients with non-small cell lung cancer

Clinica Chimica Acta

Volumn 413, Issue 13-14, 2012, Pages 1121-1126

  Peng, Wen Jia ^a   Zhang, Jun Qing ^b   Wang, Bing Xiang ^a   Pan, Hai Feng ^a   Lu, Man Man ^a   Wang, Jing ^a  

^a ANHUI MEDICAL UNIVERSITY   (China)

^b Center for Disease Control and Prevention of Hefei City   (China)

Author keywords

Hazard ratio; Meta analysis; MMP 9; Non small cell lung cancer; Prognosis

Indexed keywords

GELATINASE B;

ARTICLE; CANCER STAGING; CANCER SURVIVAL; HAZARD RATIO; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SURVIVAL PREDICTION; SYSTEMATIC REVIEW;

CARCINOMA, NON-SMALL-CELL LUNG; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MATRIX METALLOPROTEINASE 9; PROGNOSIS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 84860366293     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2012.03.012     Document Type: Article

References (35)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2009. CA Cancer J Clin 2009, 59:225-249.
2. Alberg A.J., Ford J.G., Samet J.M. Epidemiology of lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007, 132(3 Suppl.):29S-55S. American College of Chest Physicians.
3. Esposito L., Conti D., Ailavajhala R., Khalil N., Giordano A. Lung cancer: are we up to the challenge?. Curr Genomics Nov 2010, 11(7):513-518.
4. Paesmans M., Sculier J.P., Libert P., et al. Prognostic factors for survival in advanced non-small-cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1,052 patients. The European Lung Cancer Working Party. J Clin Oncol 1995, 13:1221-1230.
5. Qian Q., Wang Q., Zhan P., et al. The role of matrix metalloproteinase 2 on the survival of patients with non-small cell lung cancer: a systematic review with meta-analysis. Cancer Invest 2010, 28:661-669.
6. Martin B., Paesmans M., Berghmans T., et al. Role of Bcl-2 as a prognostic factor for survival in lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer 2003, 89(1):55-64.
7. Zhuang Y., Yin H.T., Yin X.L., Wang J., Zhang D.P. High p27 expression is associated with a better prognosis in East Asian non-small cell lung cancer patients. Clin Chim Acta 2011, 412(23-24):2228-2231.
8. Basset P., Bellocq J.P., Wolf C., et al. A novel metalloproteinases gene specifically expressed in stromal cells of breast carcinomas. Nature 1990, 348:699-704.
9. Fujise N., Nanashima A., Taniguchi Y., et al. Prognostic impact of Cathepsin B and matrix metalloproteinase-9 in pulmonary adenocarcinomas by immunohistochemical study. Lung Cancer 2000, 19-26.
10. Ondo K., Sugio K., Koji Y., et al. The significance of serum active matrixmetalloproteinase-9 in patients with non-small cell lung cancer. Lung Cancer 2004, 205-213.
11. Mook O.R., Frederiks W.M., Van Noorden C.J. The role of gelatinases in colorectal cancer progression and metastasis. Biochim Biophys Acta 2004, 1705:69-89.
12. Zucker S., Lysik R.M., DiMassimo B.I., et al. Plasma assay of gelatinase B: tissue inhibitor of metalloproteinase complexes in cancer. Cancer 1995, 76:700-708.
13. Zeng Z.S., Huang Y., Cohen A.M., Guillem J.G. Prediction of colorectal cancer relapse and survival via tissue RNA levels of matrix metalloproteinase-9. J Clin Oncol 1996, 14:3133-3140.
14. Cox G., Jones J.L., O'Byrne K.J. Matrix metalloproteinase 9 and the epidermal growth factor signal pathway in operable non-small cell lung cancer. Clin Cancer Res 2000, 6:2349-2355.
15. Sienel W., Hellers J., Morresi-Hauf A., et al. Prognostic impact of matrix metalloproteinase-9 in operable non-small cell lung cancer. Int J Cancer 2003, 103:647-651.
16. Parmar M.K., Torri V., Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 1998, 17:2815-2834.
17. Higgins J.P., Thompson S.G. Quantifying heterogeneity in a meta-analysis. Stat Med 2002, 21:1539-1558.
18. Egger M., Davey Smith G., Schneider M., Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997, 315:629-634.
19. Begg C.B., Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994, 50:1088-1101.
20. Takemoto N., Tada M., Hida Y., et al. Low expression of reversion-inducing cysteine-rich protein with Kazal motifs (RECK) indicates a shorter survival after resection in patients with adenocarcinoma of the lung. Lung Cancer Dec 2007, 58(3):376-383.
21. Cox G., Louise Jones J., Andi A., Abrams K.R., O'Byrne K.J. Bcl-2 is an independent prognostic factor and adds to a biological model for predicting outcome in operable non-small cell lung cancer. Lung Cancer Dec 2001, 34(3):417-426.
22. Swinson D.E., Cox G., O'Byrne K.J. Coexpression of epidermal growth factor receptor with related factors is associated with a poor prognosis in non-small-cell lung cancer. Br J Cancer Oct 4 2004, 91(7):1301-1307.
23. Chen X.L., Wang L.C., Zhang W.G., Chen X.Y., Sun Z.M. Correlations of S100A4 and MMP9 expressions to infiltration, metastasis and prognosis of non-small cell lung cancer. J South Med Univ 2008, 28(7):1254-1258.
24. Kim S.J., Rabbani Z.N., Dewhirst M.W., et al. Expression of HIF-1alpha, CA IX, VEGF, and MMP-9 in surgically resected non-small cell lung cancer. Lung Cancer Sep 2005, 49(3):325-335.
25. Swinson D.E., Jones J.L., Cox G., Richardson D., Harris A.L., O'Byrne K.J. Hypoxia-inducible factor-1 alpha in non small cell lung cancer: relation to growth factor, protease and apoptosis pathways. Int J Cancer Aug 10 2004, 111(1):43-50.
26. Shou Y., Hirano T., Gong Y., et al. Influence of angiogenetic factors and matrix metalloproteinases upon tumour progression in non-small-cell lung cancer. Br J Cancer Nov 30 2001, 85(11):1706-1712.
27. Ishikawa S., Takenaka K., Yanagihara K., et al. Matrix metalloproteinase-2 status in stromal fibroblasts, not in tumor cells, is a significant prognostic factor in non-small-cell lung cancer. Clin Cancer Res Oct 1 2004, 10(19):6579-6585.
28. Pinto C.A., Carvalho P.E., Antonângelo L., et al. Morphometric evaluation of tumor matrix metalloproteinase 9 predicts survival after surgical resection of adenocarcinoma of the lung. Clin Cancer Res Aug 1 2003, 9(8):3098-3104.
29. Shao W., Wang W., Xiong X.G., et al. Prognostic impact of MMP-2 and MMP-9 expression in pathologic stage IA non-small cell lung cancer. J Surg Oncol Dec 2011, 104(7):841-846.
30. Martins S.J., Takagaki T.Y., Silva A.G., Gallo C.P., Silva F.B., Capelozzi V.L. Prognostic relevance of TTF-1 and MMP-9 expression in advanced lung adenocarcinoma. Lung Cancer Apr 2009, 64(1):105-109.
31. Grossi F., Spizzo R., Bordo D., et al. Prognostic stratification of stage IIIA pN2 non-small cell lung cancer by hierarchical clustering analysis of tissue microarray immunostaining data: an Alpe Adria Thoracic Oncology Multidisciplinary Group study (ATOM 014). J Thorac Oncol Sep 2010, 5(9):1354-1360.
32. Shimanuki Y., Takahashi K., Cui R., et al. Role of serum vascular endothelial growth factor in the prediction of angiogenesis and prognosis for non-small cell lung cancer. Lung Jan-Feb 2005, 183(1):29-42.
33. Swinson D.E., Jones J.L., Richardson D., Cox G., Edwards J.G., O'Byrne K.J. Tumour necrosis is an independent prognostic marker in non-small cell lung cancer: correlation with biological variables. Lung Cancer 2002, 37(3):235-240.
34. Malats N., Bustos A., Nascimento C.M., et al. P53 as a prognostic marker for bladder cancer: a meta-analysis and review. Lancet Oncol 2005, 6:678-686.
35. Radzikowska E., Głaz P., Roszkowski K. Lung cancer in women: age, smoking, histology, performance status, stage, initial treatment and survival. Population-based study of 20 561 cases. Ann Oncol 2002, 13(7):1087-1093.